Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues

Smoking Cessation Clinical Trial

— SKIP  

Official title:

Smoking Cessation Facilitated by Glucagon-like Peptide-1 (GLP-1) Analogues - a Randomized, Double-blind, Placebo-controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03204396
• Other study ID #: 2017-00286
• Status: Completed
• Phase: Phase 2
• Start date: June 26, 2017
• Est. completion date: August 30, 2022

Study information

• Verified date: September 2022
• Source: University Hospital, Basel, Switzerland
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Cigarette smoking is the leading preventable cause of premature death worldwide. However smoking is a very difficult addiction to break whereby main reasons for not quitting or relapsing after cessation are the nicotine withdrawal syndrome and post-cessational weight gain. GLP-1 analogues are well known to stimulate insulin secretion and to reduce energy intake and therefore body weight. Recent findings from animal and human studies suggest a role of GLP-1 in the pathophysiology of addiction. The putative role of GLP-1 analogues in nicotine reward regulation combined with its weight reducing effects might be of major interest in view of novel pharmacotherapeutic options for smoking cessation. - Substudy "fMRI": This substudy is to evaluate effects of Dulaglutide treatment on functional neuronal changes in smokers who want to quit smoking. - Substudy "Energy": This substudy is to investigate the effect of Dulaglutide (Trulicity®) on REE and further parameters associated with energy metabolism (bodycomposition, haemodynamic parameters and catecholamine action) in a subset of patients recruited for the main trial.

Description:

Cigarette smoking is the leading preventable cause of premature death worldwide. However smoking is a very difficult addiction to break and despite established smoking cessation programs quit rates are low, especially in the real-life setting. The main reasons for not quitting or relapsing after cessation are the nicotine withdrawal syndrome and post-cessational weight gain. GLP-1 analogues are well known to stimulate insulin secretion and to reduce energy intake and therefore body weight. Recent findings from animal and human studies suggest a role of GLP-1 in the pathophysiology of addiction. The putative role of GLP-1 analogues in nicotine reward regulation combined with its weight reducing effects might be of major interest in view of novel pharmacotherapeutic options for smoking cessation. - Substudy "fMRI" (60 patients): Supposing that GLP-1 and analogues modulates nicotine induces reward system this substudy is to analyze if treatment with Dulaglutide (Trulicity®) attenuates craving and therefore functional brain activation. It is to evaluate effects of Dulaglutide treatment on functional neuronal changes in smokers who want to quit smoking. - Substudy "Energy" (60 patients): The aim of the substudy "Energy" is to investigate the effect of Dulaglutide (Trulicity®) on REE and further parameters associated with energy metabolism (bodycomposition, haemodynamic parameters and catecholamine action) in a subset of patients recruited for the main trial.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 256
• Est. completion date: August 30, 2022
• Est. primary completion date: July 30, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria for the main study:

• Age 18 to 75 years
• Daily smokers who are willing to quit and exhibit one of the following criteria: =10 cigarettes per day or
• At least moderate nicotine dependence defined by a Fagerstroem Score of =5 Points or
• Tobacco associated disease
• Treatment with varenicline (Champix®)

Additional Inclusion Criteria for the "substudy fMRI":

• Only patients aged 18-50 years are eligible

Additional Inclusion Criteria for the "substudy Energy":

• BMI of 18-30 kg/m2

Exclusion Criteria for the main study:

• Pregnancy (incl. wish to become pregnant within next 3 months) or breast feeding
• Pre-existing Treatment with GLP-1 agonists
• History of pancreatitis
• Severe renal insufficiency (estimated glomerular Filtration rate smaller than 30 ml/min/1.73 m2)
• Instable psychiatric conditions
• Anorexia nervosa

Additional Exclusion Criteria for the "substudy fMRI":

• Medical conditions that affect brain function (e.g. stroke, epilepsy, space occupying lesions, multiple sclerosis, Parkinson's disease, dementia, transient ischemic attack),
• Current use of medications that alter brain function
• Current illicit drug abuse including marijuana (alcohol = 1 drink per day allowed)
• Claustrophobia, cardiac pacemaker, electronic device or ferromagnetic metal foreign bodies

Related Conditions & MeSH terms

• Body Weight Changes
• Craving
• Glucagon-like Peptide-1
• Smoking Cessation
• Weight Change, Body

Intervention

Drug:
• Dulaglutide
Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.
• 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])
Application of 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl]) once weekly for 12 weeks

Locations

Country	Name	City	State
Switzerland	Universitätsspital Basel	Basel

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Point prevalence abstinence rate at week 24 and 52	Point prevalence abstinence rate at weeks 24 and 52 of dulaglutide treatment and SOC versus SOC alone, confirmed with end-expiratory exhaled carbon monoxide measurements of 10 ppm or less	52 weeks
Other	Prolonged abstinence rate at week 24 and 52		52 weeks
Other	Smoking reduction at week 12, 24, and 52		52 weeks
Other	Change of craving at week 4 and 12 relative to baseline		12 weeks
Other	Change of body weight in kg (and BMI [kg/m²]) at week 4, 8, 24, and 52		52 weeks
Other	Change in haemoglobin A1c levels at week 12, 24, and 52		52 weeks
Other	Craving measured by a Visual Analogue Scale (VAS) in the substudy "fMRI"	Behavioural endpoint of the substudy fMRI. The VAS rating scale includes seven steps from no craving to high craving.	at week 12
Other	Working memory performance investigated by the N-back task score in the substudy "fMRI"	Behavioural endpoint of the substudy fMRI. During the N-back task, all subjects see series of letters with an interstimulus interval of 2 s. Each stimulus is presented for 1 s. During a baseline (0-back) condition, subjects are required to press the button with the right hand when the letter "X" appears. During 1-back and 2-back conditions, participants are instructed to press the button if the currently presented letter is the same as that presented 1 (1-back condition) or 2 trials beforehand (2-back condition). The three conditions will be presented in ten alternating 30 s blocks (2 × 1-back, 3 × 2-back and 5 × 0-back) matched for the number of target letters per block (i.e., 2 or 3), in a pseudo-random order.	at week 12
Other	Blood oxygenated level dependent (BOLD) signal in fMRI in the substudy "fMRI"	Functional neuronal changes are assessed through the surrogate of blood oxygenated level dependent (BOLD) signal, an indirect measure of neural activity.	at week 12
Other	Change in structural plasticity of grey and white matter in fMRI in the substudy "fMRI"	Change in structural plasticity of grey and white matter in regions parts of the reward pathway (i.e. anterior cingulate cortex, insula, striatum) and in subcortical regions. One T1 sequence and one DTI sequence will be performed to investigate changes in grey and white matter.	at week 0 and at week 12
Other	Change of resting energy expenditure (REE) in the substudy "Energy"	Kcal per 24 hours. It is assessed by indirect calorimetry measuring volume of oxygen uptake (VO2) and expelled volume of carbon dioxide (VO2) in ml/min and calculated by the Weir Equation REE = [3.9 * (VO2) + 1.1 (VCO2)] * 1.44. The respiratory quotient (RQ) is calculated by dividing VCO2 by VO2.	at week 0 and at week 12
Other	Change in body composition in the substudy "Energy"	Body composition is assessed by bioelectrical impedance analysis. Measures are muscle and fat mass as a proportion (%) of total body weight.	at week 0 and at week 12
Other	Change in haemodynamic parameters in the substudy "Energy"	Blood pressure (mmHg), heart rate (beats per minute), cardiac index (l/min/m2), and peripheral vascular resistance (Pa*[s/m3]) assessed by non-invasive thoracic bioimpedance (HOTMAN®)	at week 0, 12, 24, 52
Other	Change in sympathetic activity in the substudy "Energy"	Plasma catecholamine (epinephrine and norepinephrine) and neuropeptide Y (NPY)* levels measured in pg/ml. NPY is a 36 aminoacid peptide well known to potentiate the action of catecholamine postsynaptically through the Y1 receptor and inhibit presynaptically the catecholamine secretion through the Y2 receptor	at week 0 and at week 12
Primary	Point prevalence abstinence rate at week 12	Point prevalence abstinence rate at week 12 of dulaglutide treatment and Standard of care (SOC) versus SOC alone, confirmed with end-expiratory exhaled carbon monoxide measurements of 10 ppm or less	12 weeks
Secondary	Change in Body weight	Change in body weight in kg (and BMI [kg/m²]) relative to baseline at week 12 of dulaglutide treatment versus placebo.	12 weeks